Stock listing

NASDAQ:XBIO Xenetic Biosciences, Inc. Stock

Home listing (NASDAQ) of Xenetic Biosciences, Inc.

Follow Xenetic Biosciences, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:XBIO

$1.40 USD -0.13 (-8.5%)

Close on Nov 20, 2026

Past year -39.4% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$1.25 – $1.56 USDNov 20, 2026
Volume
21,759 sharesNov 20, 2026
Market cap
$3.28M USDAt the close on Nov 20, 2026 · price × 2.34M shares outstanding
52-week range
$1.25 – $4.94 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$193,658 USDMedian day 22,400 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Xenetic Biosciences, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:XBIO · Home$1.40 USD-0.13 (-8.5%)21,759$1.55$1.56$1.25$1.53Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:XBIO · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$1.40-0.13-8.5%$1.55$1.56$1.2521,759
$1.53-0.08-5.0%$1.58$1.58$1.528,956
$1.61+0.12+8.1%$1.59$1.61$1.549,791
$1.49-0.17-10.2%$1.65$1.745$1.4317,504
$1.660.000.0%$1.765$1.837$1.669,666
$1.66-0.206-11.0%$1.76$1.797$1.6521,490
$1.866+0.066+3.7%$1.77$1.90$1.773,780
$1.80+0.002+0.1%$1.69$1.895$1.694,444
$1.798-0.073-3.9%$1.85$1.948$1.7982,541
$1.871+0.006+0.3%$1.825$1.969$1.7585,547
$1.865-0.145-7.2%$1.99$1.99$1.7836,228
$2.01-0.07-3.4%$2.12$2.164$2.0110,807
$2.08+0.02+1.0%$2.06$2.127$2.0211,455
$2.06+0.01+0.5%$2.09$2.259$2.0029,671
$2.05-0.07-3.3%$2.14$2.15$1.9532,564
$2.12+0.02+1.0%$2.12$2.21$2.0833,875
$2.10+0.275+15.1%$1.95$2.135$1.89136,342
$1.825-0.025-1.4%$1.81$1.90$1.78110,103
$1.85+0.13+7.6%$1.70$1.859$1.5845,666
$1.72-0.21-10.9%$1.90$1.90$1.7222,100
$1.93-0.09-4.5%$2.03$2.04$1.9018,900
$2.02+0.02+1.0%$2.00$2.03$1.976,800
$2.00+0.07+3.6%$1.96$2.05$1.9611,500
$1.93-0.06-3.0%$1.93$1.95$1.8510,100
$1.99-0.02-1.0%$1.98$2.00$1.9217,500
$2.01-0.09-4.3%$2.09$2.10$1.88551,400
$2.100.000.0%$2.07$2.14$2.0712,600
$2.10-0.02-0.9%$2.14$2.175$2.0433,900
$2.12-0.01-0.5%$2.14$2.27$2.118,500
$2.13+0.01+0.5%$2.195$2.231$2.1310,200
$2.12-0.09-4.1%$2.18$2.18$2.1013,600
$2.21+0.09+4.2%$2.11$2.21$2.1115,600
$2.12-0.08-3.6%$2.19$2.341$2.1014,700
$2.20-0.04-1.8%$2.23$2.29$2.199,500
$2.240.000.0%$2.30$2.33$2.1143,200
$2.24-0.08-3.4%$2.335$2.335$2.2113,400
$2.32+0.06+2.7%$2.26$2.335$2.2230,400
$2.26-0.07-3.0%$2.34$2.35$2.2512,300
$2.33-0.06-2.5%$2.37$2.475$2.2334,700
$2.39-0.08-3.2%$2.42$2.53$2.3350,700
$2.47-0.05-2.0%$2.56$2.56$2.2864,000
$2.52-0.05-1.9%$2.65$2.65$2.4390,300
$2.57-0.42-14.0%$2.99$2.99$2.436152,600
$2.99+0.22+7.9%$2.81$3.10$2.80145,600
$2.77+0.31+12.6%$2.50$2.80$2.30413,700
$2.46+0.27+12.3%$2.27$2.46$2.15667,700
$2.19-2.08-48.7%$2.75$2.789$1.871,514,500
$4.27-0.06-1.4%$4.33$4.33$4.0885,900
$4.33+0.43+11.0%$4.00$4.33$3.85266,800
$3.90-0.17-4.2%$4.07$4.11$3.83737,700
$4.07-0.145-3.4%$4.15$4.20$4.0615,500
$4.215-0.065-1.5%$4.26$4.30$4.1126,800
$4.28-0.39-8.4%$4.67$4.76$4.0086,000
$4.67+0.04+0.9%$4.73$4.904$4.4179,200
$4.63+0.38+8.9%$4.27$4.939$4.27139,100
$4.25+0.02+0.5%$4.23$4.432$4.0824,900
$4.23+0.04+1.0%$4.20$4.25$4.0025,900
$4.19+0.21+5.3%$3.99$4.30$3.95430,200
$3.98+0.01+0.3%$4.01$4.06$3.9019,600
$3.97+0.11+2.8%$3.91$4.00$3.8623,900
$3.86+0.04+1.0%$3.78$3.88$3.7022,400
$3.82+0.01+0.3%$3.81$3.82$3.5827,364
$3.81+0.22+6.1%$3.74$4.05$3.53102,789
$3.59+0.20+5.9%$3.36$3.73$3.1884,256
$3.39+0.03+0.9%$3.41$3.41$3.289,269

Splits

2 splits since 2019 · NASDAQ:XBIO · every price before a split is adjusted for it

DayRatioWhat
1-for-10Consolidation
1-for-12Consolidation
Ticker
NASDAQ:XBIO
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Xenetic Biosciences, Inc. news

Xenetic Biosciences, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
11 in the last 12 months · 103 in all · newest Nov 13, 2026 · oldest 2019
Decks
8 decks · latest Sep 16, 2026

Where Xenetic Biosciences, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:XBIO · Home listing · This pageNASDAQUnited StatesUSD
BOATS:XBIOBOATSUnited StatesUSD
Munich:3XB0MunichGermanyEUR
gettex:3XB0gettexGermanyEUR

Valuation

EV/sales −0.8× against a median of −12.8×: 3rd lowest of 4 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$2.53M USD
P/E
Loss
EV/sales
−0.8×
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
0.7×
Gross margin
16.7%
Operating margin
−129.6%
Net margin
−123.7%
Debt to equity
0.0×
Beta vs S&P 500
1.46

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Xenetic Biosciences, Inc. · NASDAQ:XBIOUS$3.28M−US$2.53Mn/a−0.8×n/a0.7×−123.7%0.0×1.46
Liminatus Pharma, Inc. · NASDAQ:LIMNUS$3.37MUS$1.80Mn/an/an/a11.2×n/a4.8×0.94
Aprea Therapeutics, Inc. · NASDAQ:APREUS$3.25M−US$34.60Mn/an/an/a0.1×n/a0.0×0.73
Spago Nanomedical AB · OMXSTO:SPAGOUS$3.21MUS$22,125n/a5.6×n/a1.0×n/a0.0×n/a
Kiora Pharmaceuticals, Inc. · NASDAQ:KPRXUS$3.19M−US$12.81Mn/a−12.8×n/a0.2×n/a0.0×1.54
Azitra Inc · AMEX:AZTRUS$3.13M−US$618,677n/an/an/a0.7×n/a0.0×0.60
NuCana plc · NASDAQ:NCNAUS$3.12M−US$21.39Mn/an/an/a0.1×n/a0.0×1.58
Revive Therapeutics Ltd. · CSE:RVVUS$3.10MUS$3.14Mn/an/an/an/an/an/a0.56
Skye Bioscience, Inc. · NASDAQ:SKYEUS$3.10M−US$1.71Mn/an/an/a2.3×n/a0.0×0.85
Creative Medical Technology Holdings, Inc. · NASDAQ:CELZUS$3.06M−US$3.79Mn/a−1,263×n/a0.4×n/a0.0×1.53
Oncology Pharma Inc. · OTC:ONPHUS$3.04Mn/an/an/an/an/an/an/a1.62
Median of the othersUS$3.13M−US$1.71M−12.8×0.6×0.0×0.94

Forecasts

Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.

Price target
40.00 USD · Analysts' mean
EPS, year to Dec 2026
-3.32 · 1 analyst

Team and board

Officers

OfficerRole
James F. ParslowInterim Chief Executive Officer and Chief Financial Officer

Board

DirectorRole
Alexey VinogradovNon-Executive Director
Dmitry GenkinNon-Executive Director
Firdaus Jal DastoorNon-Executive Director
Grigory G. BorisenkoNon-Executive Director
Moshe MizrahyNon-Executive Director
Roger KornbergNon-Executive Director

Events

QuarterResultsShare move
Q3 2026Nov 12, 2026−11.1%
Q2 2026Aug 11, 2026+6.8%
Q1 2026May 13, 2026+2.8%
Q4 2025Mar 12, 2026 · After close+9.5%
Q3 2025Nov 12, 2025 · After close−2.6%
Q2 2025Aug 12, 2025 · After close+7.2%
Q1 2025May 7, 2025 · After close+0.3%
Q4 2024Mar 18, 2025 · After close+1.9%
Q3 2024Nov 12, 2024 · After close−11.6%
Q2 2024Aug 13, 2024 · After close−6.0%
All 20 quarters
QuarterResultsShare move
Q1 2024May 9, 2024 · After close−3.6%
Q4 2023Mar 21, 2024 · After close−2.3%
Q3 2023Nov 9, 2023 · After close−1.4%
Q2 2023Aug 10, 2023 · After close+0.8%
Q1 2023May 11, 2023 · After close−17.5%
Q4 2022Mar 22, 2023 · After close0.0%
Q3 2022Nov 9, 2022 · After close+4.3%
Q2 2022Aug 11, 2022 · After close+4.8%
Q1 2022May 12, 2022 · After close+6.5%
Q4 2021Mar 22, 2022 · After close+4.8%

Open Events

Decks

DeckKindSlidesDate
Merger or Acquisition (September 2026)Merger or acquisition25 slidesSep 16, 2026
Merger or Acquisition (September 2026)Merger or acquisition26 slidesSeptember 2026
Investor Presentation (June 2023)Investor deck30 slidesJun 6, 2023
Investor Presentation (September 2021)Investor deck28 slidesSep 13, 2021
Investor Presentation (January 2021)Investor deck24 slidesJan 19, 2021
Investor Presentation (September 2019)Investor deck32 slidesSep 9, 2019
Corporate Update (June 2019)Corporate update32 slidesJun 18, 2019
Merger or Acquisition (March 2019)Merger or acquisition34 slidesMar 4, 2019

Open Decks

Financings

RaiseDate
Public offering of common stock
Announced: about US$4.5M · US$6.12 a share · Canaccord Genuity
Dealers: Canaccord Genuity (lead)
Use of proceeds: Working capital and other general corporate purposes
Oct 10, 2025

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue2.98M2.50M2.54M1.71M1.16M436.9K17.1K07.58M3.00M
Cost of revenue27.0K35.5K15.8K156.1K36.4K
Gross profit2.98M2.50M2.54M1.71M1.16M436.9K17.1K-15.8K7.43M2.96M
Research and development3.07M3.29M3.49M4.77M3.16M1.73M4.89M2.88M4.06M43.7M
Selling, general and administrative2.75M3.42M3.56M3.65M3.74M3.40M4.73M4.39M6.94M6.69M
Operating income-2.83M-4.20M-4.52M-6.72M-5.75M-13.9M-12.9M-7.28M-3.57M-47.4M
Depreciation and amortization153.3K0001.00K4.20K15.8K23.8K36.4K
EBITDA-4.05M-4.52M-6.72M-5.75M-13.9M-12.9M-7.26M-3.54M-47.4M
Interest expense165.6K101.6K18.4M111.8K24.1K1.82K729.6K
Income before tax-2.68M-3.96M-4.13M-6.55M-5.65M-13.8M-12.8M-7.30M-3.60M-54.2M
Income tax00000-2.92M0000
Net income-2.68M-3.96M-4.13M-6.55M-5.65M-10.9M-12.8M-7.30M-3.60M-54.2M
Earnings per share, basic-1.58-2.57-2.71-4.61-0.55-1.70-6.33-9.66-0.41-7.84
Earnings per share, diluted-1.58-2.57-2.71-4.61-0.55-1.70-6.33-9.66-0.41-7.84

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents7.88M6.17M8.98M13.1M18.2M11.5M10.4M571.6K5.53M4.05M
Short-term investments67.0K67.0K
Receivables500.0K03.00M
Inventory1
Current assets8.05M6.59M9.59M13.7M18.7M12.4M11.1M1.19M5.88M8.34M
Property, plant and equipment0007574.96K27.8K42.4K
Goodwill09.24M3.28M3.28M3.28M
Total assets8.36M6.90M10.6M14.7M19.8M13.2M21.5M14.4M19.2M21.0M
Accounts payable258.1K283.6K240.8K287.4K362.5K327.4K931.1K934.1K786.8K1.01M
Current liabilities968.0K894.3K809.6K1.07M1.42M936.9K1.42M1.60M1.94M1.87M
Total debt27.0K62.5K20.0K
Total liabilities968.0K894.3K809.6K1.07M1.42M964.0K4.33M4.52M4.86M4.80M
Shareholders' equity7.40M6.01M9.80M13.6M18.4M12.2M17.2M9.91M14.3M16.2M
Shares outstanding2.29M1.54M1.54M1.52M13.4M8.75M6.07M783.9K8.72M4.59M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-2.29M-2.82M-4.11M-4.65M-4.74M-4.27M-6.40M-6.46M1.49M-8.79M
Capital spending00-1-500.0K0000-9.26K-16.8K
Free cash flow-2.29M-2.82M-4.11M-5.15M-4.74M-4.27M-6.40M-6.46M1.48M-8.80M
Cash from investing0-500.0K002.00K22.5K-9.26K-16.8K
Cash from financing4.00M016011.5M5.43M16.1M1.48M012.7M
Dividends paid-39.5M
Share buybacks1.29M5.43M3.03M1.48M39.5M
Change in cash1.72M-2.82M-4.11M-5.15M6.72M1.16M9.73M-4.96M1.48M3.92M

Open Financials

Filings

FilingDateTypeFiled with
DEFA14A · Additional proxy materialNov 13, 2026Meeting noticeSEC
8-K · Current reportNov 13, 2026ResultsSEC
10-Q · Quarterly reportNov 12, 2026Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 12, 2026Big-stake noticeSEC
8-K · Current reportSep 23, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeSep 18, 2026Big-stake noticeSEC
8-K · Current reportSep 16, 2026Material contractSEC
8-K · Current reportAug 7, 2026ResultsSEC
10-Q · Quarterly reportAug 6, 2026Quarterly reportSEC
SCHEDULE 13G · Big-stake noticeMay 29, 2026Big-stake noticeSEC
Show 200 filings
FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedMay 14, 2026Big-stake noticeSEC
8-K · Current reportMay 13, 2026ResultsSEC
10-Q · Quarterly reportMay 12, 2026Quarterly reportSEC
10-K/A · Annual report, amendedApr 24, 2026Annual reportSEC
8-K · Current reportApr 24, 2026Management or board changeSEC
4 · Change in ownershipApr 23, 2026Insider tradeSEC
8-K · Current reportMar 13, 2026ResultsSEC
10-K · Annual reportMar 12, 2026Annual reportSEC
SCHEDULE 13G · Big-stake noticeFeb 12, 2026Big-stake noticeSEC
8-K · Current reportJan 9, 2026Current reportSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
DEFA14A · Additional proxy materialDec 11, 2025Meeting noticeSEC
8-K · Current reportDec 11, 2025Current reportSEC
8-K · Current reportNov 13, 2025ResultsSEC
10-Q · Quarterly reportNov 12, 2025Quarterly reportSEC
ARS · Annual report to shareholdersOct 31, 2025Annual reportSEC
DEFA14A · Additional proxy materialOct 31, 2025Meeting noticeSEC
DEF 14A · Proxy statementOct 31, 2025Meeting noticeSEC
8-K · Current reportOct 14, 2025Material contractSEC
424B5 · ProspectusOct 10, 2025Offer documentSEC
424B5 · ProspectusOct 10, 2025Offer documentSEC
8-K · Current reportAug 13, 2025ResultsSEC
10-Q · Quarterly reportAug 12, 2025Quarterly reportSEC
8-K · Current reportMay 14, 2025ResultsSEC
10-Q · Quarterly reportMay 13, 2025Quarterly reportSEC
10-K/A · Annual report, amendedMay 13, 2025Annual reportSEC
10-K/A · Annual report, amendedApr 29, 2025Annual reportSEC
8-K · Current reportApr 10, 2025Current reportSEC
8-K/A · Current report, amendedMar 19, 2025Current reportSEC
8-K · Current reportMar 19, 2025ResultsSEC
10-K · Annual reportMar 18, 2025Annual reportSEC
4 · Change in ownershipDec 13, 2024Insider tradeSEC
4 · Change in ownershipDec 13, 2024Insider tradeSEC
4 · Change in ownershipDec 13, 2024Insider tradeSEC
4 · Change in ownershipDec 13, 2024Insider tradeSEC
8-K · Current reportDec 13, 2024Meeting outcomeSEC
8-K · Current reportNov 13, 2024ResultsSEC
10-Q · Quarterly reportNov 12, 2024Quarterly reportSEC
8-K · Current reportNov 7, 2024Material contractSEC
EFFECT · Notice that a registration is effectiveNov 4, 2024Other filingsSEC
8-K · Current reportOct 31, 2024Management or board changeSEC
ARS · Annual report to shareholdersOct 31, 2024Annual reportSEC
DEFA14A · Additional proxy materialOct 31, 2024Meeting noticeSEC
DEF 14A · Proxy statementOct 31, 2024Meeting noticeSEC
CORRESP · Letter to the SECOct 30, 2024Other filingsSEC
UPLOAD · Letter from the SECOct 25, 2024Other filingsSEC
S-3 · Registration statementOct 21, 2024Offer documentSEC
8-K · Current reportAug 14, 2024ResultsSEC
10-Q · Quarterly reportAug 13, 2024Quarterly reportSEC
25-NSEJul 18, 2024Other filingsSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
8-K · Current reportJun 21, 2024Management or board changeSEC
8-K · Current reportMay 22, 2024Management or board changeSEC
8-K · Current reportMay 10, 2024ResultsSEC
10-Q · Quarterly reportMay 9, 2024Quarterly reportSEC
10-K/A · Annual report, amendedApr 26, 2024Annual reportSEC
8-K · Current reportMar 22, 2024ResultsSEC
10-K · Annual reportMar 21, 2024Annual reportSEC
SC 13D/A · Big-stake notice, amendedMar 18, 2024Big-stake noticeSEC
8-K · Current reportFeb 12, 2024Current reportSEC
4 · Change in ownershipDec 18, 2023Insider tradeSEC
3 · Initial statement of ownershipDec 18, 2023Insider tradeSEC
4 · Change in ownershipDec 13, 2023Insider tradeSEC
4 · Change in ownershipDec 13, 2023Insider tradeSEC
4 · Change in ownershipDec 13, 2023Insider tradeSEC
4 · Change in ownershipDec 8, 2023Insider tradeSEC
4 · Change in ownershipDec 8, 2023Insider tradeSEC
4 · Change in ownershipDec 8, 2023Insider tradeSEC
4 · Change in ownershipDec 8, 2023Insider tradeSEC
4 · Change in ownershipDec 8, 2023Insider tradeSEC
4 · Change in ownershipDec 8, 2023Insider tradeSEC
8-K · Current reportDec 8, 2023Meeting outcomeSEC
ARS · Annual report to shareholdersNov 13, 2023Annual reportSEC
DEF 14A · Proxy statementNov 13, 2023Meeting noticeSEC
8-K · Current reportNov 13, 2023ResultsSEC
10-Q · Quarterly reportNov 9, 2023Quarterly reportSEC
SC 13D/A · Big-stake notice, amendedSep 18, 2023Big-stake noticeSEC
8-K · Current reportAug 11, 2023ResultsSEC
10-Q · Quarterly reportAug 10, 2023Quarterly reportSEC
SC 13D · Big-stake noticeJun 15, 2023Big-stake noticeSEC
8-K · Current reportJun 6, 2023Current reportSEC
8-K · Current reportJun 2, 2023Current reportSEC
8-K · Current reportMay 12, 2023Current reportSEC
8-K · Current reportMay 11, 2023ResultsSEC
10-Q · Quarterly reportMay 11, 2023Quarterly reportSEC
10-K/A · Annual report, amendedApr 28, 2023Annual reportSEC
8-K · Current reportMar 23, 2023ResultsSEC
10-K · Annual reportMar 22, 2023Annual reportSEC
8-K · Current reportDec 22, 2022Meeting outcomeSEC
4 · Change in ownershipDec 9, 2022Insider tradeSEC
4 · Change in ownershipDec 9, 2022Insider tradeSEC
4 · Change in ownershipDec 9, 2022Insider tradeSEC
4 · Change in ownershipDec 9, 2022Insider tradeSEC
4 · Change in ownershipDec 9, 2022Insider tradeSEC
4 · Change in ownershipDec 9, 2022Insider tradeSEC
8-K · Current reportDec 9, 2022Meeting outcomeSEC
8-K · Current reportDec 2, 2022Current reportSEC
8-K · Current reportNov 10, 2022ResultsSEC
10-Q · Quarterly reportNov 9, 2022Quarterly reportSEC
SC 13G · Big-stake noticeOct 21, 2022Big-stake noticeSEC
DEFA14A · Additional proxy materialOct 17, 2022Meeting noticeSEC
DEF 14A · Proxy statementOct 17, 2022Meeting noticeSEC
DOct 13, 2022Other filingsSEC
8-K · Current reportOct 12, 2022FinancingSEC
PRE 14A · Preliminary proxy statementOct 3, 2022Meeting noticeSEC
8-K · Current reportAug 12, 2022ResultsSEC
10-Q · Quarterly reportAug 11, 2022Quarterly reportSEC
8-K · Current reportJul 7, 2022Material contractSEC
8-K · Current reportJun 6, 2022Current reportSEC
10-Q · Quarterly reportMay 12, 2022Quarterly reportSEC
DMay 4, 2022Other filingsSEC
10-K/A · Annual report, amendedApr 28, 2022Annual reportSEC
8-K · Current reportApr 27, 2022Acquisition or disposalSEC
4 · Change in ownershipMar 28, 2022Insider tradeSEC
4 · Change in ownershipMar 28, 2022Insider tradeSEC
4 · Change in ownershipMar 28, 2022Insider tradeSEC
8-K · Current reportMar 23, 2022ResultsSEC
10-K · Annual reportMar 22, 2022Annual reportSEC
S-8 · Registration statement for employee plansDec 30, 2021Offer documentSEC
4 · Change in ownershipDec 9, 2021Insider tradeSEC
4 · Change in ownershipDec 9, 2021Insider tradeSEC
4 · Change in ownershipDec 9, 2021Insider tradeSEC
4 · Change in ownershipDec 9, 2021Insider tradeSEC
4 · Change in ownershipDec 9, 2021Insider tradeSEC
8-K · Current reportDec 9, 2021Meeting outcomeSEC
DEFA14A · Additional proxy materialDec 2, 2021Meeting noticeSEC
8-K · Current reportNov 19, 2021Material contractSEC
424B5 · ProspectusNov 19, 2021Offer documentSEC
8-K · Current reportNov 16, 2021Material contractSEC
8-K · Current reportNov 12, 2021ResultsSEC
10-Q · Quarterly reportNov 12, 2021Quarterly reportSEC
EFFECT · Notice that a registration is effectiveOct 25, 2021Other filingsSEC
CORRESP · Letter to the SECOct 20, 2021Other filingsSEC
S-3/A · Registration statement, amendedOct 20, 2021Offer documentSEC
UPLOAD · Letter from the SECOct 19, 2021Other filingsSEC
DEF 14A · Proxy statementOct 15, 2021Meeting noticeSEC
8-K · Current reportOct 15, 2021Material contractSEC
S-3 · Registration statementOct 12, 2021Offer documentSEC
8-K · Current reportSep 13, 2021Current reportSEC
EFFECT · Notice that a registration is effectiveAug 24, 2021Other filingsSEC
CORRESP · Letter to the SECAug 19, 2021Other filingsSEC
UPLOAD · Letter from the SECAug 18, 2021Other filingsSEC
S-3 · Registration statementAug 13, 2021Offer documentSEC
8-K · Current reportAug 13, 2021ResultsSEC
10-Q · Quarterly reportAug 12, 2021Quarterly reportSEC
DAug 3, 2021Other filingsSEC
8-K · Current reportJul 28, 2021Material contractSEC
8-K · Current reportJul 16, 2021Management or board changeSEC
8-K · Current reportMay 12, 2021ResultsSEC
10-Q · Quarterly reportMay 11, 2021Quarterly reportSEC
10-K/A · Annual report, amendedApr 28, 2021Annual reportSEC
4 · Change in ownershipMar 22, 2021Insider tradeSEC
4 · Change in ownershipMar 22, 2021Insider tradeSEC
4 · Change in ownershipMar 22, 2021Insider tradeSEC
8-K · Current reportMar 17, 2021ResultsSEC
10-K · Annual reportMar 16, 2021Annual reportSEC
8-K · Current reportJan 19, 2021Current reportSEC
SC 13G · Big-stake noticeDec 21, 2020Big-stake noticeSEC
8-K · Current reportDec 16, 2020Current reportSEC
8-K · Current reportDec 14, 2020Material contractSEC
424B5 · ProspectusDec 11, 2020Offer documentSEC
8-K · Current reportDec 9, 2020Meeting outcomeSEC
4 · Change in ownershipDec 8, 2020Insider tradeSEC
4 · Change in ownershipDec 8, 2020Insider tradeSEC
4 · Change in ownershipDec 8, 2020Insider tradeSEC
4 · Change in ownershipDec 8, 2020Insider tradeSEC
4 · Change in ownershipDec 8, 2020Insider tradeSEC
8-K · Current reportNov 13, 2020ResultsSEC
10-Q · Quarterly reportNov 12, 2020Quarterly reportSEC
8-K · Current reportOct 30, 2020Current reportSEC
UPLOAD · Letter from the SECOct 14, 2020Other filingsSEC
DEF 14A · Proxy statementOct 13, 2020Meeting noticeSEC
CORRESP · Letter to the SECOct 6, 2020Other filingsSEC
UPLOAD · Letter from the SECOct 5, 2020Other filingsSEC
PRE 14A · Preliminary proxy statementSep 30, 2020Meeting noticeSEC
8-K · Current reportAug 13, 2020ResultsSEC
10-Q · Quarterly reportAug 12, 2020Quarterly reportSEC
8-K · Current reportJun 24, 2020Current reportSEC
8-K · Current reportJun 16, 2020Material contractSEC
8-K · Current reportMay 19, 2020Material contractSEC
10-Q · Quarterly reportMay 14, 2020Quarterly reportSEC
8-K · Current reportMay 14, 2020ResultsSEC
10-K/A · Annual report, amendedApr 29, 2020Annual reportSEC
8-K · Current reportApr 24, 2020Current reportSEC
4/A · Change in ownership, amendedApr 2, 2020Insider tradeSEC
S-8 · Registration statement for employee plansApr 1, 2020Offer documentSEC
8-K · Current reportMar 27, 2020ResultsSEC

This page holds 200 of 488 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Xenetic Biosciences, Inc.’s releases · as of Nov 6, 2026

Common shares
2,343,181
Fully diluted
2,343,181

Fully diluted

LineSharesAs of
Common shares2,343,181Nov 6, 2026

Share count over time

CountShares
Nov 6, 20262,343,181

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueChange vs Jun 30Filed
Renaissance Technologies55,0402.3%US$128K−62,400Nov 12, 2026
Hrt Financial LP29,6411.3%US$68,000NewNov 13, 2026
Vanguard24,2281.0%US$56,209+11,547Nov 13, 2026
Geode Capital17,4230.74%US$40,439No changeNov 6, 2026
Citadel15,3460.65%US$35,603NewNov 16, 2026
Allworth Financial LP6,4060.27%US$14,862NewNov 17, 2026
JTC Employer Solutions Trustee Ltd2,7000.12%US$6,000No changeNov 9, 2026
Jones Financial Companies Lllp1,4660.06%US$3,504NewNov 13, 2026
UBS1,0130.04%US$2,350NewNov 10, 2026
SBI Securities Co., Ltd.1,0030.04%US$2,327+3Oct 21, 2026
All 13 holders
HolderSharesOf the companyValueChange vs Jun 30Filed
Morgan Stanley150<0.01%US$348No changeNov 13, 2026
Darwin Wealth Management, LLC2<0.01%US$4No changeNov 9, 2026
Parallel Advisors, LLC1<0.01%US$2NewNov 3, 2026

Funds

HolderSharesOf the companyValueChangeAs of
Fidelity Extended Market Index Fund13,7250.59%US$42,822+3,990May 31, 2026
Vanguard Extended Market Index Fund12,6810.54%US$36,902+5,950Jun 30, 2026
Fidelity Nasdaq Composite Index Fund2,0700.09%US$6,458No changeMay 31, 2026
Fidelity Series Total Market Index Fund1,3880.06%US$4,331No changeMay 31, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Darlene Deptula-Hicks
Other companies: Aldeyra Therapeutics, Inc. (Director · Since at least Jun 9, 2026); T2 Biosystems, Inc. (SVP & Chief Financial Officer · May 1, 2017 – Jun 6, 2017 · Past); Palvella Therapeutics, Inc. (SVP, Chief Financial Officer · Jun 29, 2015 – Jun 13, 2016 · Past); icad inc (Exec VP of Finance, CFO · Sep 11, 2006 – Mar 29, 2011 · Past)
Director · Nov 1, 2016 – Aug 9, 2017 · Past
Adam Logal
Other companies: Non-Invasive Monitoring Systems, Inc. (Director · Since at least Sep 3, 2025); OPKO Health, Inc. (Sr. Vice President, CFO · Since at least Feb 19, 2021)
Director · Dec 4, 2020 – Dec 6, 2023 · Past
Edward J Benz Jr
Other companies: Candel Therapeutics, Inc. (Director · Since at least Jul 26, 2021); Deciphera Pharmaceuticals LLC (Director · Sep 27, 2017 – Jun 11, 2024 · Past)
Director · Nov 21, 2016 – Aug 9, 2017 · Past
Roger Kornberg
Other companies: Cocrystal Pharma, Inc. (Chairman of the Board, Chief Scientist and Chairman of Scientific Advisory Board · Since at least Mar 17, 2014); Big Digital Energy, Inc. (Director · Jun 11, 2013 – Jun 11, 2013 · Past)
Non-Executive Director · Since at least Nov 1, 2016
Curtis Lockshin
Other companies: Phio Pharmaceuticals Corp. (Director · Since at least Mar 1, 2021)
Chief Sciencific Officer · Dec 4, 2019 – Dec 11, 2023 · Past
James F. Parslow
Other companies: World Energy Solutions Inc (CFO, Treasurer, Secretary · Apr 22, 2009 – Jan 5, 2015 · Past)
Interim Chief Executive Officer and Chief Financial Officer · Since at least Apr 3, 2017
Jeffrey F Eisenberg
Other companies: MabVax Therapeutics Holdings Inc (Director · Feb 19, 2016 – Feb 21, 2018 · Past)
Chief Executive Officer, Director · Nov 1, 2016 – Dec 11, 2023 · Past
Moshe Mizrahy
Other companies: InMode Ltd. (Chief Executive Officer, Director · Since at least Mar 18, 2026)
Non-Executive Director · Since at least Dec 6, 2023
Alexey VinogradovNon-Executive Director · Since at least Jul 19, 2019
Dmitry GenkinNon-Executive Director · Since at least Aug 14, 2017
All 14 people
PersonSeat
Firdaus Jal DastoorNon-Executive Director · Since at least Nov 1, 2016
Grigory G. BorisenkoDirector · Since at least Dec 7, 2022
James Eric CallawayDirector · Dec 4, 2019 – Dec 6, 2023 · Past
Michael Scott MaguireCEO, Director · Nov 1, 2016 – Dec 20, 2016 · Past

Open People

Log in to ask 6ix AI your own questions about Xenetic Biosciences, Inc.